A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.

Parkinson Disease Clinical Trial

Official title: A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.

Status Not yet recruiting

Clinical Trial Summary

Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.

Clinical Trial Description

Evaluate the safety and tolerability of LBT-3627 in both a single and multiple ascending dose study.

Phase Ia will explore safety and tolerability first in healthy volunteers then followed by Parkinson's patients after a single dose. Dose levels will escalate per cohort.

Phase Ib will explore safety and tolerability in Parkinson's patients after multiple doses. Dose levels will escalate per cohort. ;

Related Conditions & MeSH terms

• Parkinson Disease

• NCT number: NCT06466525
• Study type: Interventional
• Source: Longevity Biotech
• Contact: Tim Porter, MBBS, FANZCA, MBioethics
• Phone: +61 450992172
• Email: Tim.Porter@avancecro.com
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: June 15, 2024
• Completion date: March 2025